Novartis reported Thursday that a Phase III trial of iptacopan met its primary endpoint in paroxysmal nocturnal hemoglobinuria (PNH) – the company’s second win in this indication in as many months.
Tag Archive for: Novartis
Novartis’ Kisqali, combined with endocrine therapy, offered almost a year of progression-free survival (PFS) for an aggressive form of HER+/HER2- metastatic breast cancer, the company announced Tuesday.
With Novartis facing a potential loss of $9 billion through 2026 from patent expirations, the company announced topline results for Pluvicto for PSMA-positive metastatic castration-resistant prostate cancer (mCRPC).
Capping a tumultuous year of legal battles, Teva Pharmaceuticals has found a new president and CEO. Effective Jan. 1, 2023, Richard Francis will take the company’s reins as Kåre Schultz retires.
The Swiss drugmaker is considering selling its ophthalmology and respiratory units, a Bloomberg report said on Wednesday, citing people familiar with the matter. The company is seeking to raise money from the possible sale of the assets to invest in cutting-edge medicines, the report said, adding that the ophthalmology unit could alone fetch about $5 billion.
The facility, bought from a Novartis unit, will be its first messenger ribonucleic acid, or mRNA, facility in Singapore and support its vaccines production for the Asia Pacific region, BioNTech said in a statement, without disclosing financial details.
After six months of searching for its next chief executive, Washington’s largest biotech firm has found its match. On Thursday, Seagen named David R. Epstein as CEO.
Much of the global pharmaceutical and biotech industry has yet to set any targets for reducing carbon emissions in line with the Paris Agreement, a new analysis has found, despite the biggest companies in the sector leading the way.
Sandoz, the generic drugs business that will be spun off its parent Novartis, will boost investment in its European antibiotics production network by 50 million euros ($50 million) on strong global demand for bacteria-fighting medicines.
Novartis’ positive-third quarter growth report Tuesday was marred slightly by several clinical setbacks that resulted in the termination of studies in liver transplant and non-small cell lung cancer.